Home › Funds › Vivo Capital, LLC › ANRO
Vivo Capital, LLC position in ANRO
ALTO NEUROSCIENCE INC · Health Care
Vivo Capital, LLC reported holding 1,359,915 shares of ANRO (ALTO NEUROSCIENCE INC) in its Q3 2026 13F filing — a position valued at US$34.7M, representing 3.94% of its reported portfolio and ranking #8 among its reported holdings. Vivo Capital, LLC has disclosed ANRO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Vivo Capital, LLC's ANRO position evolved
Vivo Capital, LLC first disclosed a stake in ANRO in Q4 2025 at 1,035,551 shares (US$18.4M). The position peaked in Q3 2026 at 1,359,915 shares, worth US$34.7M. Across 4 filings, Vivo Capital, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,359,915 shares valued at US$34.7M — an increase of 151,057 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.04M | $18.43M | New |
| Q1 2026 | 1.04M | $23.28M | Hold |
| Q2 2026 | 1.21M | $31.90M | Add |
| Q3 2026 | 1.36M | $34.72M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANRO and 13F data
ANRO (ALTO NEUROSCIENCE INC) is a Health Care company. 61 other funds we track also report a position in ANRO — the largest reported positions include Alpha Wave Global, LP (US$97.8M), Commodore Capital LP (US$71.9M), PERCEPTIVE ADVISORS LLC (US$42.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANRO
- Alpha Wave Global, LP 3.71M sh · $97.85M · Q2 2026
- Commodore Capital LP 2.72M sh · $71.87M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.61M sh · $42.49M · Q2 2026
- Spruce Street Capital LP 1.35M sh · $35.71M · Q2 2026
- ARMISTICE CAPITAL, LLC 864.00K sh · $22.80M · Q2 2026
- Affinity Asset Advisors, LLC 850.00K sh · $22.43M · Q2 2026
- Vestal Point Capital, LP 785.00K sh · $20.72M · Q2 2026
- 72 Investment Holdings, LLC 667.78K sh · $17.62M · Q2 2026
- Venrock Adviser, LLC 500.00K sh · $13.20M · Q2 2026
- Parkman Healthcare Partners LLC 429.04K sh · $11.32M · Q2 2026
- Ikarian Capital, LLC 407.34K sh · $10.75M · Q2 2026
- Saturn V Capital Management LP 182.83K sh · $4.82M · Q2 2026
More on Vivo Capital, LLC
FAQ
How long has Vivo Capital, LLC held ANRO?
Vivo Capital, LLC has disclosed ANRO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Vivo Capital, LLC's current position in ANRO?
As of Q3 2026, Vivo Capital, LLC holds 1.36M shares of ANRO (ALTO NEUROSCIENCE INC), valued at $34.72M, representing 3.94% of its reported portfolio and ranking #8.
Has Vivo Capital, LLC been buying or selling ANRO?
In the latest 13F filing (Q3 2026), Vivo Capital, LLC increased its position in ANRO. The position peaked in Q3 2026 at 1.36M shares.
Which other funds hold ANRO?
Other major institutional holders of ANRO include Alpha Wave Global, LP, Commodore Capital LP, PERCEPTIVE ADVISORS LLC, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.